The highlighted chemokine axes (CCL8-CCR2, CCL19/CCL21-CCR7, CXCL9-CXCR3, CCL3/CCL5-CCR5, and CCL20-CCR6) offer promising research avenues and potential pharmacological targets for IPF treatment. This evidence concerns the gene CCL21 and idiopathic pulmonary fibrosis.